QTX3034 in Patients With KRAS G12D Mutation
QTX3034 in Patients With KRAS G12D Mutation
Recruiting · NCT06227377 · Registry updated 2026-04-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| QTX3034 in Patients With KRAS G12D Mutation | Solid Tumors | Recruiting | Phase 1 | 2026-04-27 | NCT06227377 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Quanta Therapeutics | 3 |
14 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University | Durham | United States | 160 |
| Florida Cancer Specialists | Sarasota | United States | 47 |
| MD Anderson | Houston | United States | 56 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Montefiore Medical Center | The Bronx | United States | 79 |
| NEXT Oncology Virginia | Fairfax | United States | 40 |
| NYU Langone Health | New York | United States | 403 |
| Sarah Cannon Research Institute (SCRI) | Denver | United States | 3 |
| SCRI- Nashville | Nashville | United States | 1 |
| START San Antonio, LLC | San Antonio | United States | 5 |
| Stephenson Cancer Center | Oklahoma City | United States | 32 |
| UCLA Hematology/Oncology | Los Angeles | United States | 12 |
| University of Utah, Huntsman Cancer Center | Salt Lake City | United States | 3 |
| Yale Cancer Center | New Haven | United States | 21 |